Generic Challenge for UTHR's Remodulin - Analyst Blog
February 08 2012 - 10:36AM
Zacks
United Therapeutics Corporation (UTHR) is
facing a patent challenge for its lead product, Remodulin
(treprostinil) injection. Sandoz, Novartis’ (NVS)
generic unit, is seeking approval for its generic version of
Remodulin (10 mg/mL).
The Paragraph IV Certification Notice Letter was received from
Sandoz on Feb 3, 2012. Sandoz has filed an Abbreviated New Drug
Application (ANDA) with the US Food and Drug Administration (FDA)
for its generic version of Remodulin.
Sandoz is challenging three patents – one that expires in
October 2014, another that expires in October 2017 and a third that
expires in March 2029. According to Sandoz, all these patents are
invalid, not enforceable and will not be infringed by Sandoz’
product.
Remodulin, the key revenue generator at United Therapeutics,
accounts for more than 55% of sales – the entry of generic
competition would, therefore, be a major blow to the company. In
such a scenario, we believe United Therapeutics will leave no stone
unturned in its efforts to delay the entry of generics.
We believe United Therapeutics will file a patent infringement
lawsuit against Sandoz within 45 days so that Sandoz’s product
cannot receive FDA approval until a court rules in Sandoz’ favor or
for up to 30 months, whichever comes earlier. Remodulin sales
totaled $320 million in the first nine months of 2011.
Neutral on United Therapeutics
We currently have a Neutral recommendation on United
Therapeutics, which carries a Zacks #3 Rank (short term “Hold”
rating). The company is well-positioned to gain share in the
pulmonary arterial hypertension (PAH) market. Remodulin continues
to look very strong in both the intravenous (IV) and subcutaneous
(SC) forms.
With the approval of Adcirca and Tyvaso, United Therapeutics now
has a varied range of therapies available for the treatment of PAH.
We believe the company’s PAH product portfolio will drive strong
top-and bottom-line growth.
United Therapeutics’ competitors in the PAH market include
companies like Gilead (GILD) and
Pfizer (PFE) among others. We believe competition
will continue to increase with several companies working on
bringing additional therapies to the market.
GILEAD SCIENCES (GILD): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
UTD THERAPEUTIC (UTHR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024